Published 2020
| Version v1
Publication
Overall survival of CDK4/6-inhibitors-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis
- Creators
- Schettini, Francesco
- Giudici, Fabiola
- Giuliano, Mario
- Cristofanilli, Massimo
- Arpino, Grazia
- Del Mastro, Lucia
- Puglisi, Fabio
- De Placido, Sabino
- Paris, Ida
- De Placido, Pietro
- Venturini, Sergio
- De Laurentis, Michelino
- Conte, PierFranco
- Juric, Dejan
- Llombart-Cussac, Antonio
- Pusztai, Lajos
- Prat, Aleix
- Jerusalem, Guy
- Di Leo, Angelo
- Generali, Daniele
- Others:
- Schettini, Francesco
- Giudici, Fabiola
- Giuliano, Mario
- Cristofanilli, Massimo
- Arpino, Grazia
- Del Mastro, Lucia
- Puglisi, Fabio
- De Placido, Sabino
- Paris, Ida
- De Placido, Pietro
- Venturini, Sergio
- De Laurentis, Michelino
- Conte, Pierfranco
- Juric, Dejan
- Llombart-Cussac, Antonio
- Pusztai, Lajo
- Prat, Aleix
- Jerusalem, Guy
- Di Leo, Angelo
- Generali, Daniele
Description
CDK4/6-inhibitors (CDK4/6i)+endocrine therapy (ET) prolonged progression-free survival as first/second-line therapy for hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (MBC) prognosis. Given the recent publication of overall survival (OS) data for the three CDK4/6i, we performed a meta-analysis to identify a more precise and reliable benefit from such treatments in specific clinical subgroups.
Additional details
- URL
- http://hdl.handle.net/11567/1023935
- URN
- urn:oai:iris.unige.it:11567/1023935
- Origin repository
- UNIGE